07:00 , Apr 18, 2016 |  BC Week In Review  |  Clinical News

Atu027: Phase Ib/IIa final data

Final data from the Phase IIa portion of the open-label, German Phase Ib/IIa Atu027-I-02 trial in 23 patients with locally advanced or metastatic pancreatic adenocarcinoma showed that twice-weekly Atu027 for 4 weeks plus once-weekly gemcitabine...
07:00 , Oct 1, 2015 |  BC Innovations  |  Product R&D

Escaping the liver

Having addressed one of the two big problems of RNAi delivery - getting therapeutic levels of the molecules inside cells - Arrowhead Research Corp. now believes it has solved the second, with a modification to...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

Atu027: Additional Phase IIa data

A post hoc analysis of the subgroup of 19 patients with metastatic pancreatic adenocarcinoma in the Phase IIa portion of the open-label, German Phase Ib/IIa Atu027-I-02 trial showed that twice-weekly Atu027 for 4 weeks plus...
01:21 , Apr 3, 2015 |  BC Extra  |  Financial News

Funding roundup: Raptor, Conatus, Silence, Northwest, Trinity, Egalet

Rare disease play Raptor Pharmaceutical Corp. (NASDAQ:RPTP) raised $85.5 million through the sale of 9.5 million shares at $9 in a follow-on underwritten by Citigroup; Leerink; Cowen; JMP Securities; and Janney Montgomery Scott. The company...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

Atu027: Preliminary Phase IIa data

Preliminary data from the Phase IIa portion of the open-label, German Phase Ib/IIa Atu027-I-02 trial in 23 patients with locally advanced or metastatic pancreatic adenocarcinoma showed that twice-weekly Atu027 for 4 weeks plus once-weekly gemcitabine...
01:54 , Mar 24, 2015 |  BC Extra  |  Clinical News

Silence golden on pancreatic cancer data

Silence Therapeutics plc (LSE:SLN) climbed 50.5p (21%) to 288p after preliminary Phase IIa data suggested the biotech's Atu027 had a dose-dependent effect in advanced pancreatic cancer patients. The study included 23 patients receiving one of...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

Atu027: Completed Phase Ib/IIa enrollment

Silence said it completed enrollment of 24 patients with locally advanced or metastatic pancreatic adenocarcinoma in the Phase IIa portion of an open-label, German Phase Ib/IIa trial of Atu027 plus gemcitabine in 4-week cycles. The...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality. The...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Clinical News

Atu027: Phase Ib/IIa ongoing

Silence said a DSMB recommended continuation into the main portion of an open-label, German Phase Ib/IIa trial evaluating Atu027 plus gemcitabine in 4-week cycles in about 30 patients. The decision was based on safety data...
07:00 , Apr 15, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) jumped $5.13 (64%) to $13.10 on Thursday after announcing that FDA said existing data, including a single Phase III trial, were sufficient to support an NDA for pimavanserin to treat...